The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

aduro.com

Executives

13

Aduro BioTech Management Team

13 Team Members

Aduro BioTech has 13 executives. Aduro BioTech's founder is Henry Rapoport. Aduro BioTech's current Chief Executive Officer is Stephen Isaacs.

Name

Work History

Title

Status

Stephen Isaacs

Chief Executive Officer

Current

Gregory Schafer

Chief Operating Officer

Current

Dirk G Brockstedt

Senior Vice President

Current

Henry Rapoport

Founder

Former

Sam Rose

Founder

Former

Name

Stephen Isaacs

Gregory Schafer

Dirk G Brockstedt

Henry Rapoport

Sam Rose

Work History

Title

Chief Executive Officer

Chief Operating Officer

Senior Vice President

Founder

Founder

Status

Current

Current

Current

Former

Former

You May Also Like

T
TechnoVax

TechnoVax is a privately held biotechnology company and specializes in vaccine development. The company aims to begin clinical trials within the next 18 months.

O
Osprey Pharmaceuticals

Osprey Pharmaceuticals is a privately held biotechnology company focused on developing and commercializing a first-in-class family of therapeutic proteins (Leukocyte Population Modulators) capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The company's proprietary LPMs selectively and systematically destroy disease-related leukocytes by infiltrating the chemokine system that regulates the movement and activity of leukocytes.

N
Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic- related disorders including acute ischemic stroke and catheter occlusion and preclinical candidates NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease and NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. In addition, Nuvelo expects to leverage its expertise in cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.

F
FIBREX Medical

FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company is focused on pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. Per FIBREX, while inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction.

A
AgaPharm

AgaPharm is developing a prescription eye drop for Diabetics. The drug aims to offer a simple, low-cost treatment that can deliver a safe and effective dose to the eye, preventing or slowing down the onset of diabetic blindness and cataract. The company's Research Partner is the Biotechnology Research Institute at the National Research Council of the Government of Canada.

Noveome Biotherapeutics Logo
Noveome Biotherapeutics

Noveome Biotherapeutics is regenerative medicine company focused on the research, development and clinical use of its technology platform, derived from human placental cells. This platform provides a new approach to tissue regeneration and repair in a wide range of medical conditions. Noveome's technology platform is derived from a population of cells isolated from full-term placental tissue that is normally discarded following delivery of a baby. There is no interruption in the development of the baby to procure this tissue.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.